Warsaw Stock Exchange: Ryvu Therapeutics 1Q23 in line with expectations (NEUTRAL)STOCKSGPW’s Analytical Coverage Support Programme 3.0
Warsaw Stock Exchange: Ryvu Therapeutics – ValuationSTOCKSGPW’s Analytical Coverage Support Programme 3.0
Ryvu Therapeutics: Termination of partnering deal with Galapagos, Valuation summary and moreSTOCKSGPW’s Analytical Coverage Support Programme 3.0
Ryvu Therapeutics: Milestones payments from Exelixis, Share issue and 4Q22 results & Conference highlightsSTOCKSGPW’s Analytical Coverage Support Programme 3.0
WSE: Ryvu Therapeutics - One more partnering deal in 2023e?STOCKSGPW’s Analytical Coverage Support Programme 3.0
12:31 13.03US Markets React to Inflation Data and Trade Concerns; Focus on Economic Indicators and Corporate Earnings